Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Voyager Therapeutics closes $45mm Series A financing

Executive Summary

Third Rock Ventures launched Voyager Therapeutics Inc. and provided the start-up with $45mm in Series A financing to support work, over at least the next three years, on gene therapeutics for fatal CNS diseases. Third Rock, which has incubated Voyager for the last couple years, says it would be willing to add another VC, including a corporate backer, to later tranches.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies